Vaspin (human) BioAssay(TM) ELISA Kit (Visceral Adipose Tissue-derived Serine Protease Inhibitor, Serpin A12, OL-64)

Vaspin (Visceral adipose tissue-derived serpin; Serpin A12), a serine protease inhibitor (serpin), is an insulin-sensitizing adipocytokine that has been isolated from both visceral and subcutaneous white adipose tissue. Based on recent findings, vaspin is suggested to regulate immune responses and inflammation and was found to be correlated with various metabolic parameters. Human vaspin blood levels are significantly increased in type 2 diabetes mellitus and obese patients. Thus vaspin may represent a novel biomarker for obesity and impaired insulin sensitivity and might serve as a new therapeutic target of metabolic syndrome.\n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: +4 degrees C

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

045382

Size

96Tests

References

Product Reference: \n?Serum vaspin concentrations in human obesity and type 2 diabetes: B.S. Youn, et al.; Diabetes 57, 372 (2008)\n?Serum levels of the adipokine vaspin in relation to metabolic and renal parameters: J. Seeger, et al.; J. Clin. Endocrinol. Metab. 93, 247 (2008)\n?Metformin decreases the Adipokine Vaspin in overweight women with the polycystic ovary syndrome: Concomitant improvement in insulin sensitivity and a decrease in insulin resistance: B.K. Tan, et al.; Diabetes 57, 1501 (2008)\n?Vaspin: a novel serpin with insulin-sensitizing effects: J. Wada; Expert Opin. Investig. Drugs 17, 327 (2008)\n?Vaspin serum concentrations in patients with carotid stenosis: G. Aust, et al.; Atherosclerosis 204, 262 (2009)\n?Serum vaspin levels in type 2 diabetic women in relation to microvascular complications: N.E. Gulcelik, et al.; Eur. J. Endocrinol. 160, 65 (2009)\n?Serum Visceral Adipose Tissue-Derived Serine Protease Inhibitor Concentrations in Human Obesity and Polycystic Ovary Syndrome: H.F. Escobar-Morreale, et al.; Diabetes Care 32, e6 (2009)\n?Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months: L. IbГЎГ±ez, et al.; Clin. Endocrinol. (Oxf) 71, 351 (2009)\n?Preliminary report: circulating levels of the adipokine vaspin in gestational diabetes mellitus and preeclampsia: H. Stepan, et al.; Metabolism 59, 1054 (2010)\n?Circadian Rhythm of Serum Vaspin in Healthy Male Volunteers: Relation to Meals: E. Jeong, et al.; J. Clin. Endocrinol. Metab. 95, 1869 (2010)\n?Serum Vaspin Concentrations in Relation to Insulin Sensitivity Following RYGB-Induced Weight Loss: A. Handisurya, et al.; Obes. Surg. 20, 198 (2010)\n?Serum chemerin and vaspin in non-alcoholic fatty liver disease: M. Kukla, et al.; Scand. J. Gastroenterol. 45, 235 (2010)\n?Chemerin, vaspin and insulin resistance in chronic hepatitis C: M. Kukla, et al.; J. Viral Hepat. 17, 661 (2010)\n?Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men: J.K. Chou, et al.; Eur. J. Appl.Physiol. 108, 347 (2010)\n?Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects: H.M. Chang, et al.; Metabolism 59, 1276 (2010)\n?Reduced serum vaspin concentrations in obese children following shortterm intensive lifestyle modification: M.K. Lee, et al.; Clin. Chim. Acta 411, 381 (2010)\n?Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance: H.M. Chang, et al.; Obesity (Silver Spring) 18, 2105 (2010)\n?Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans: C. von Loeffelholz, et al.; Eur. J. Endocrinol. 162, 507 (2010)\n?Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis: L. Senolt, et al.; Ann. Rheum. Dis. 69, 1410 (2010)\n?Comparison of orlistat treatment and placebo in obese type 2 diabetic patients: G. Derosa, et al.; Expert. Opin. Pharmacother. 11, 1971 (2010)\n?Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients: G. Derosa, et al.; Fundam. Clin. Pharmacol. (Epub ahead of print) (2010)\n?Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus: H.O. El-Mesallamy, et al.; Metabolism 60, 63 (2011)\n?Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients: G. Derosa, et al.; Metabolism 60, 421 (2011)\n?Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism: G.A. Martos-Moreno, et al.; Int. J. Obes. (Lond) (Epub ahead of print) (2011)\n?Omentin-1 and vaspin are present in the fetus and neonate, and perinatal concentrations are similar in normal and growth-restricted pregnancies: D.D. Briana, et al.; Metabolism 60, 486 (2011)\n?Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children: A. K

Additional Info

Detects human vaspin. Does not cross-react with human RBP4, human adiponectin, human Nampt, human leptin or human RELM-beta.

Alternative Names

Visceral Adipose Tissue-derived Serine Protease Inhibitor, Serpin A12, OL-64